An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Biogen Inc.
VERDICT
The label
Markup
read at $200.14
Biogen holds its Markup at $200.14.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-27
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 13 days
Price
$200.14
Valuation
21.52 trailing · 12.19 forward price to earnings
Values screen
PASS· score 83.7
Beta
0.16
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 41% discount to our $281.25 fair value, narrow competitive moat, 1.90% revenue growth.
Read at
$200.14
21.52 P/E · 12.19 fwd
Our fair value
$281.25
41% discount
Analyst target (avg)
$225.00
+12% to current
Target low $157.00Analyst target rangeTarget high $300.00
▲ current $200.14 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$200.14
you are here
Conservative
$270.86
+35%
Analyst avg
$225.00
+12%
Our fair value
$281.25
+41%
Analyst high
$300.00
+50%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
1.90%
Profit margin
13.81%
Debt to equity
35.18
Analyst consensus
Buy · 30 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 22.3% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 1.5% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 16.6% of assets, under the 49% limit.Pass
Revenue purityOnly 1.3% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Old multiple sclerosis drugs at a discount
Think of Biogen as the firm still keeping the lights on for multiple sclerosis patients who rely on drugs such as Tysabri and Tecfidera. Those treatments keep delivering even as newer rivals arrive, and the shares sit at 205 with a forward multiple of just 12.5 times. Our fair value sits at 281, a 36 percent margin of safety, while revenue edges up 2 percent and margins hold at 14 percent. The ethical screen clears without issue.
The narrow moat and 8 percent return on equity explain why the market has not bid the stock higher. Yet the business still throws off cash from established therapies, and thirty analysts carry a buy rating with a 225 median target. That leaves room for the price to close toward our own number if execution stays steady.
Slow top line growth and a narrow moat remain real constraints. Any fresh competition or pricing pressure in the multiple sclerosis space could cap upside and leave the shares range bound. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
BIIB trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219. Entered 2026-07-23 · Distribution
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219.
2026-07-18Markup$195.34+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (29 analysts) rates it buy, with a mean price target of $219.
2026-07-03Markup$195.34+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$195.34Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
